Scorpion Therapeutics, Inc.

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector

“I’m always keeping an eye on anything that’s going to the capital markets, whether that’s interest rates... a big change in the regulatory environment...anything that impacts capital markets and inve

With many big pharmas anxious to fill their portfolios with new commercial sellers and biotechs running low on cash, 2025 is expected to be a big year for deals and M&A across the biopharma sector